Pravibismane
![]() | |
| Clinical data | |
|---|---|
| Other names | BisEDT |
| Identifiers | |
| |
| CAS Number | |
| PubChem CID | |
| DrugBank | |
| ChemSpider | |
| UNII | |
| Chemical and physical data | |
| Formula | C6H12Bi2S6 |
| Molar mass | 694.48 g·mol−1 |
| 3D model (JSmol) | |
| |
| |
Pravibismane (BisEDT) is an experimental antibiotic medication for topical use. It is in clinical trials for infections secondary to diabetic foot ulcer.[1][2]
References
- ↑ Baker B (December 2020). "1289. Pravibismane is a Potent, Broad Spectrum Anti-Infective Small Molecule that Rapidly Disrupts Bacterial Bioenergetics and Halts Bacterial Growth". Open Forum Infectious Diseases. 7 (Suppl 1): S659–S660. doi:10.1093/ofid/ofaa439.1472. PMC 7776586.
- ↑ Lipsky BA, Kim PJ, Murphy B, McKernan PA, Armstrong DG, Baker BH (April 2024). "Topical pravibismane as adjunctive therapy for moderate or severe diabetic foot infections: A phase 1b randomized, multicenter, double-blind, placebo-controlled trial". International Wound Journal. 21 (4) e14817. doi:10.1111/iwj.14817. PMC 10988878. PMID 38567778.
{{cite journal}}: CS1 maint: unflagged free DOI (link)
